8-K 1 d8k.htm FORM 8-K Form 8-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): September 18, 2003

 

CuraGen Corporation

(Exact name of registrant as specified in its charter)

 

   

Delaware

    0-23223
   06-1331400
    
    (State or other jurisdiction
of incorporation)		   

(Commission

File Number)

  

(IRS Employer

Identification No.)

    

 

555 Long Wharf Drive, 11th Floor

New Haven, Connecticut 06511

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (203) 401-3330

 

Item 5.    Other Events and Regulation FD Disclosure.

 

On September 18, 2003, 454 Life Sciences, the Registrant’s majority-owned subsidiary and an innovative developer of genome-scale analysis technologies, issued a press release announcing that it raised $20M from existing shareholders. The Registrant led the investment with $16M of financing, increasing its majority ownership to 66%, and was joined by existing investors including Cooper Hill Partners.

 

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

Item 7.    Financial Statements and Exhibits.

 

(c)    The following exhibit is filed with this report:

 

Exhibit Number
  

Description

99.1   Press release of Registrant dated September 18, 2003.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       

CURAGEN CORPORATION

(Registrant)

Date: September 19, 2003               By:  

/s/    DAVID M. WURZER        

       

Name:

Title:

  

David M. Wurzer

Executive Vice President and

Chief Financial Officer